# A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY 1142524 in Patients After Acute Myocardial Infarction With Left-ventricular Dysfunction

> **NCT02976467** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 107 (actual)

## Conditions studied

- Myocardial Infarction

## Interventions

- **DRUG:** Fulacimstat (BAY1142524)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02976467
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-30
- **Primary completion:** 2018-07-31
- **Final completion:** 2018-09-04
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2019-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02976467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02976467, "A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY 1142524 in Patients After Acute Myocardial Infarction With Left-ventricular Dysfunction". Retrieved via AI Analytics 2026-08-13 from https://api.ai-analytics.org/clinical/NCT02976467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*